文献速递前列腺癌

MRI检出与未检出前列腺癌共存对活检策略及局灶治疗规划的影响

Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials.
PubMed 文献 · Eur Urol Oncol · 2026-06-16

本研究基于PROMIS和PICTURE试验的探索性分析,纳入306例MRI可疑象限并接受经会阴模板穿刺活检的患者,比较MRI检出与未检出前列腺癌的特征及其对局灶治疗规划的影响。结果显示MRI检出癌的Grade Group和最大癌芯长度显著高于未检出癌(p<0.001),仅基于MRI靶向活检即可充分检出高级别癌并规划局灶治疗,增加对侧系统活检仅改变9%患者的治疗模板。

要点

  • MRI检出前列腺癌的Grade Group和最大癌芯长度显著高于MRI未检出癌。
  • 仅基于MRI靶向活检即可充分检出Grade Group 2-5和3-5癌并规划局灶治疗。
  • 增加对侧半腺系统活检仅使9%患者局灶治疗模板发生改变。

核心结论

  • 在本探索性分析中,仅MRI靶向活检足以检出Grade Group 2-5和3-5癌并规划局灶治疗,增加对侧系统活检仅改变9%的局灶治疗规划。

研究设计与样本

  • 对PROMIS和PICTURE试验的探索性分析,纳入306例MRI显示1-2个可疑象限且接受5-mm经会阴模板穿刺活检的患者。

主要发现

  • 306例中240例(78%)诊断为癌症,215例(70%)有MRI检出癌,44例(14%)同时有MRI检出癌和额外的MRI未检出癌。
  • MRI检出癌的Grade Group和最大癌芯长度均显著大于MRI未检出癌(p<0.001)。
  • 基于MRI靶向活检符合局灶治疗条件的127例中,若行全腺体活检,116例(91%)无需改变治疗模板(p=0.1)。
  • 在MRI靶向活检基础上增加对侧半腺活检可识别所有需要改变治疗模板的患者,需活检人数为12。

关键数值与推荐

  • 癌症定义采用Grade Group 2-5和Grade Group 3-5。
  • 局灶治疗规划改变的定义基于全腺体活检或增加对侧半腺活检后治疗模板的调整。

临床怎么用

  • 对于MRI可见前列腺癌患者,MRI靶向活检联合病灶周围活检可能足以规划局灶治疗,对侧系统活检仅在有特定指征时添加。

局限性

  • 本研究为探索性分析,结果需前瞻性验证,尤其关于局灶治疗规划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: European Association of Urology guidelines now recommend performing magnetic resonance imaging (MRI)-targeted with peri-lesional biopsies rather than traditional systematic biopsies. In patients with MRI-detected prostate cancer, the characteristics and therapeutic implications of concomitant MRI-undetected disease requiring systematic biopsy to identify are unclear. This was investigated through exploratory analyses of the PROMIS and PICTURE trials. METHODS: Patients with one or two suspicious quadrants on MRI, either ipsilateral or contralateral, and who underwent 5-mm transperineal template mapping biopsy were included. MRI-detected and -undetected lesions were compared and the impact of systematic biopsies on focal therapy planning was assessed. Cancer definitions used were Grade Group 2-5 and Grade Group 3-5. KEY FINDINGS AND LIMITATIONS: Overall, 306 patients were included. A total of 240/306 (78%) had cancer diagnosed; 215/306 (70%) had MRI-detected cancer, with 44/306 (14%) having both MRI-detected cancer and additional MRI-undetected cancer. MRI-detected cancers had greater Grade Group and maximum cancer core length than MRI-undetected cancers (p < 0.001 for each). Of 127 patients eligible for focal therapy based on MRI-targeted biopsy alone, if whole gland biopsy were performed instead then 116/127 (91%) would not require a change to treatment template (p = 0.1). Adding contralateral hemigland biopsy to MRI-targeted biopsy identified all patients requiring a change to their treatment template. To ensure correct focal therapy planning for all, the number-needed-to-biopsy using additional contralateral hemigland biopsy instead of MRI-targeted biopsy alone was 12. CONCLUSIONS AND CLINICAL IMPLICATIONS: In this exploratory analysis, MRI-targeted biopsy alone was sufficient for detecting Grade Group 2-5 and Grade Group 3-5 cancer and was also sufficient for planning focal therapy, with the addition of contralateral systematic biopsies only altering focal therapy planning in 9%. Prospective validation of these findings, particularly regarding focal therapy planning, is needed.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Light A, Peters M, Gopalakrishnan A, et al. Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials. Eur Urol Oncol. 2026. PMID: 42303478. doi:10.1016/j.euo.2026.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。